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Material and Methods: Between January and December 2014, 
29 patients with locally advanced cervical cancer were 
underwent combination external beam radiotherapy with or 
without concomitant chemotherapy and IGBT with or without 
hybrid technique using VariSourceTM ring applicator with 
‘Siriraj Ring Cap’ extension (at least one fraction). 117 
dosimetric planning and clinical outcome of treatment were 
evaluated. 
 
Results: For high risk clinical target volume (HR CTV) the 
median was volume 37.4 cm3 (range; 15.3-76.1 cm3) and the 
median of D90 was 85.3Gy (range; 76.4-90.5Gy). The median 
of D2cc for bladder, rectum, sigmoid, and bowel loop were 
84Gy (range; 68.3-89.7Gy), 66.1Gy (range; 56.8-76.3Gy), 65.6 
(range; 49-77.1Gy), and 61.9Gy (range; 45.8-78.1Gy), 
respectively. 81.2% (95 of 117 plans) were performed using 
VariSourceTM ring applicator with ‘Siriraj Ring Cap’ 
extension, while mean of coverage of the HR CTV was 89.2% 
(range; 57-99%). 18.8% (22 of 117 plans) were applied using 
tandem with ovoids, and mean of coverage of the HR CTV 
was 79.9% (range; 53-96%). Median follow up was 10.6 
months. The actuarial 1 year loco-regional recurrence free 
survival rate was 90.5% (95% confidence interval (CI); 67-
98%), progression free survival rate was 85.7% (95% CI; 62-
95%), and overall survival rate was 95.4% (95% CI; 71-99%). 
One patient had a grade 2 late rectal complication. No grade 
3-5 late complications have been recorded so far. 
 
Conclusion: IGBT with or without hybrid technique using 
VariSourceTM titanium ring applicator with ‘Siriraj Ring Cap’ 
extension is applicable for locally advanced cervical cancer 
resulting in an excellent local control rate and limited 
morbidity. 
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Purpose or Objective: The effectiveness of radiation therapy 
in the management of cervical cancer of all stages is well 
established. Radiation therapy usually consists of a 
combination of external beam therapy and brachytherapy. 
Further exploration of new approaches and methodologies is 
a promising direction of development. Given the 
radiobiological aspects and an important economic factor, 
i.e. reduction of hospital stay. The aim of this study was to 
estimate the effectiveness of the treatment of cervical 
cancer patients using adaptive image-guided brachytherapy 
(IGBT) during split course. 
 
Material and Methods: In the period from May 2014, 38 
patients with primary cervical cancer were treated with 
combined radiotherapy using the new split-adaptive 
methodology for IGBT. We used conformal radiation 
techniques: BOX method, IMRT or RapidArc. Total dose on the 
pelvic area and regional metastases was 50 Gy. Further HDR 
IGBT brachytherapy was followed with dosimetry planning 
MRI - images. The treatment was on 1st and 2nd , 8th and 9th 
days, ring tandem applicators implantation under general 
anesthesia. Between the fractions 1 and 2 and 3 and 4, the 
patients were with applicator under the supervision of 
medical staff during the day. Monitoring planning was 
conducted according to MRI-studies; as a result treatment 
plan was composed for every 2 fractions. The position of the 
applicator in relation to the tumor and critical organs during 
the day doesn’t change provided that the methodology is 
being correctly observed. Dose plans were optimized for 
maximal tumor dose (D90) and coverage (V100 and V80). The 
dose parameters in the target volume are the following: D 90 
= 7.3 (5.9-9.1) Gy, V 100 = 91.5 (79.2-99.1) %, V 80 = 97.8 
(90.5 -100). Of the patients it was T2bN0M0 – 7 patients, 
T3bN0M0 – 5, T2b-3bN1M0 – 18, T2b-3bN1M1 – 8. 
 
Results: in the results the values of dose rates (D 2 cc / D 0,1 
cc) to organs of risk (bladder, rectum and sigmoid) are the 
following: 3.7 (1.7-7) / 4.8 (2.2 -9.4) Gy; 3.1 (1.2-6) / 4.2 
(1.4 - 8.3) and 3.9 (2.2-5.7) / 5.5 (3.5 -7.6) Gy. During 
follow-up time for 12 months no any acute or late toxicity of 
grade 2 were observed and not observed any difference in 
comparison with the fractionation scheme used previously. 
No one local recurrence were observed, regional recurrence 
in 2 (2 and 7 months), distant metastasis in 1 (12 months). 
The patients have undergone the treatment satisfactorily. 
The number of surgical implantations decreases from 4 to 2. 
According to preliminary data, local radiation reactions are 
not multiple. 
 
Conclusion: The main advantage of this method is the dose 
delivery in a shorter period of time, which allows for a 
greater control of the tumor. This method allows to reduce 
the time of course of brachytherapy to 9 days. Evaluating the 
effectiveness of treatment shows good tolerance of this 
treatment with satisfactory results. This clinical study is 
currently ongoing. 
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Purpose or Objective: To evaluate dosimetric and clinical 
findings of MRI-guided HDR brachytherapy (HDR-BQ) for 
cervical carcinoma. 
 
Material and Methods: From 2008 to 2014: 50 patients. All 
patients had a CT, MRI and pelvic-paraaortic 
lymphadenectomy. Treatment: pelvic(+/-)para-aortic3D/IMRT 
radiotherapy(45Gy) and weekly cisplatin followed by HDR-BQ 
and pelvic node/ parametrial boost 60Gy. Two implants at 
week 6th and 7 th were done: 5 fractions of 6Gy and from 
2011 4 fractions of 7Gy. MRI/TAC was done in each implant. 
There where defined: GTV, CTH-HR, CTV-IR; OAR: rectum, 
bladder and sigmoid. 
 
Results: Patients: T1b2-T2a: 3p, T2b 36p, T3a: 2p; T3B 9p; 
N0: 31p, N1 19p.With a median follow up of 50.6 months(8.1 
– 89.2 months), 5 patients had local recurrence, 6 lymph 
node recurrence, 6 distant metastasis and 36 without 
recurrence. Local control at 5 years was 88%; Ib2-IIB: 93%, III: 
70%. (p:0.07). Lymph node Regional Disease Free 
Survival(RDFS) 5y was 88%; IB2-IIB: 89%, III: 83% (p:ns); for 
pN0: 94%; pN+ iliac-paraaortic: 77% (p: 0.08). Metastasis Free 
Survival 5y was 78%; IIBN0: 78%, IIBN1: 89%, III: 63%. Overall 
